Sign In
Buy CATX
$3.56
-0.0400 (-1.11%)
At Close: Jun 03, 2026
Profusa (NASDAQ:PFSA) and Perspective Therapeutics (NASDAQ:CATX) Financial Contrast
01:08am, Saturday, 07'th Feb 2026
Perspective Therapeutics (NASDAQ: CATX - Get Free Report) and Profusa (NASDAQ: PFSA - Get Free Report) are both small-cap manufacturing companies, but which is the superior business? We will contrast
Perspective Therapeutics Announces Pricing of $175 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
08:35am, Monday, 02'nd Feb 2026
SEATTLE, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced trea
Comparing Perspective Therapeutics (NASDAQ:CATX) & Biosig Technologies (NASDAQ:STEX)
02:00am, Monday, 02'nd Feb 2026
Biosig Technologies (NASDAQ: STEX - Get Free Report) and Perspective Therapeutics (NASDAQ: CATX - Get Free Report) are both small-cap manufacturing companies, but which is the superior investment? We
Perspective Therapeutics: VMT-A-NET Presses On In SSTR2-Solid Tumor Targeting Space
03:37pm, Friday, 30'th Jan 2026
Perspective Therapeutics, Inc. retains a Strong Buy rating, driven by promising VMT-a-NET data and Sanofi deprioritizing a competing SSTR2-targeted therapy. CATX's VMT-a-NET achieved 76% progression-f
Perspective Therapeutics (NYSEAMERICAN:CATX) Shares Down 4.4% – Time to Sell?
03:30am, Tuesday, 27'th Jan 2026
Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX - Get Free Report)'s share price traded down 4.4% during trading on Monday. The stock traded as low as $2.58 and last traded at $2.59. 732,483 shares
Perspective Therapeutics, Inc. (CATX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
09:46pm, Wednesday, 14'th Jan 2026
Perspective Therapeutics, Inc. (CATX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
SEATTLE, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical develop
Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Given Average Recommendation of “Buy” by Brokerages
01:55am, Sunday, 04'th Jan 2026
Shares of Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX - Get Free Report) have been assigned a consensus rating of "Buy" from the ten brokerages that are presently covering the stock, MarketBeat
Perspective Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
07:00am, Thursday, 18'th Dec 2025
SEATTLE, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatme
Critical Survey: Perspective Therapeutics (NASDAQ:CATX) & Vyome (NASDAQ:HIND)
01:59am, Sunday, 14'th Dec 2025
Vyome (NASDAQ: HIND - Get Free Report) and Perspective Therapeutics (NASDAQ: CATX - Get Free Report) are both small-cap manufacturing companies, but which is the superior business? We will compare the
Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Receives Average Rating of “Buy” from Brokerages
01:46am, Wednesday, 10'th Dec 2025
Shares of Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX - Get Free Report) have been given an average recommendation of "Buy" by the ten analysts that are presently covering the company, MarketBea
Perspective Therapeutics to Participate in Upcoming December Conferences
07:00am, Thursday, 20'th Nov 2025
SEATTLE, Nov. 20, 2025 (GLOBE NEWSWIRE) -- November 20, 2025 – Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pione
Perspective Therapeutics, Inc. (CATX) Presents at UBS Global Healthcare Conference 2025 Transcript
11:11pm, Tuesday, 11'th Nov 2025
Perspective Therapeutics, Inc. ( CATX ) UBS Global Healthcare Conference 2025 November 11, 2025 4:15 PM EST Company Participants Joel Sendek - Chief Financial Officer Annie Cheng - Vice President of I
Perspective Therapeutics Provides Recent Business Highlights and Reports 3Q 2025 Results
04:05pm, Monday, 10'th Nov 2025
SEATTLE, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical develop
Perspective Therapeutics to Participate in Upcoming November Conferences
07:00am, Friday, 31'st Oct 2025
SEATTLE, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatme
